Triptorelin

What is Triptorelin?#

Triptorelin is a synthetic decapeptide analogue of gonadotropin-releasing hormone (GnRH, also known as luteinizing hormone-releasing hormone or LHRH) that is used as a pharmaceutical agent for the treatment of hormone-dependent conditions. It is one of several GnRH agonists approved for clinical use worldwide, marketed under brand names including Trelstar (United States), Decapeptyl (Europe), and Gonapeptyl (various markets).

The peptide was developed through a rational drug design approach that modified the native GnRH decapeptide sequence to improve metabolic stability and receptor binding affinity. The key structural modification is the substitution of L-glycine at position 6 with D-tryptophan, which confers resistance to enzymatic degradation and increases binding affinity to the GnRH receptor. This single amino acid change transforms a rapidly metabolized hypothalamic hormone with a half-life of minutes into a therapeutically useful drug with sustained biological activity.

Mechanism of Action#

Triptorelin's mechanism of action is a textbook example of pharmacological paradox: a receptor agonist that ultimately produces antagonist-like effects through receptor desensitization. Understanding this mechanism requires knowledge of the hypothalamic-pituitary-gonadal (HPG) axis.

The Hypothalamic-Pituitary-Gonadal Axis#

Under normal physiology, the hypothalamus releases GnRH in a pulsatile fashion, approximately every 60-120 minutes. This pulsatile release pattern is critical: it stimulates the anterior pituitary gonadotroph cells to synthesize and secrete luteinizing hormone (LH) and follicle-stimulating hormone (FSH). These gonadotropins then act on the gonads, stimulating testosterone production in males and estrogen and progesterone production in females.

Biphasic Response#

Triptorelin administration produces a characteristic biphasic response in the HPG axis.

Initial stimulatory phase (flare): During the first 1-2 weeks of treatment, continuous GnRH receptor stimulation by triptorelin actually increases LH and FSH secretion, leading to a transient rise in sex steroid hormones. Testosterone levels in men may temporarily increase by 50-100% above baseline during this flare period. In women, estradiol levels similarly increase transiently.

Desensitization phase: Continuous, non-pulsatile GnRH receptor stimulation leads to receptor downregulation and desensitization of the pituitary gonadotroph cells. After 2-4 weeks, LH and FSH levels fall to castrate or hypogonadal levels. Downstream sex steroid hormones decrease correspondingly: testosterone falls to castrate levels in men (below 50 ng/dL), and estradiol falls to postmenopausal levels in women.

This desensitization is mediated by GnRH receptor internalization and degradation, uncoupling of the receptor from its G-protein signaling cascade, reduction in GnRH receptor mRNA expression, and altered gonadotropin gene expression in pituitary cells. The process is reversible: discontinuation of triptorelin allows gradual restoration of pulsatile GnRH signaling and recovery of the HPG axis over weeks to months.

Clinical Applications#

Advanced Prostate Cancer#

The primary oncological indication for triptorelin is the treatment of advanced (metastatic) prostate cancer. Prostate cancer is androgen-dependent: testosterone stimulates the growth and survival of prostate cancer cells through activation of the androgen receptor. By reducing testosterone to castrate levels, triptorelin deprives the tumor of its primary growth signal.

Androgen deprivation therapy (ADT) with GnRH agonists like triptorelin is a cornerstone of prostate cancer management. It is used as primary therapy for locally advanced or metastatic disease, neoadjuvant or adjuvant therapy with radiation for intermediate and high-risk localized disease, and treatment of biochemical recurrence after definitive local therapy.

Multiple randomized controlled trials have demonstrated that GnRH agonist therapy provides survival benefits equivalent to surgical castration (bilateral orchiectomy) while avoiding the psychological and physical morbidity of surgery. The availability of extended-release depot formulations (1-month, 3-month, and 6-month) has improved convenience and compliance.

Endometriosis#

Triptorelin is approved for the management of endometriosis, a condition in which endometrial tissue grows outside the uterus, causing pain, inflammation, and infertility. By suppressing estrogen production to postmenopausal levels, triptorelin induces a pseudomenopausal state that causes regression of endometrial implants and relief of symptoms including pelvic pain, dysmenorrhea, and dyspareunia.

Treatment courses are typically limited to 6 months due to the adverse effects of prolonged estrogen deprivation on bone density and other tissues. Add-back therapy with low-dose hormone replacement may be used to mitigate these effects during extended treatment.

Central Precocious Puberty#

Central precocious puberty (CPP) occurs when the HPG axis is activated prematurely, typically defined as the onset of secondary sexual characteristics before age 8 in girls or age 9 in boys. Triptorelin suppresses the premature activation of the HPG axis, halting or slowing pubertal progression and preserving growth potential by preventing premature epiphyseal fusion.

Treatment continues until the age-appropriate time for puberty, at which point discontinuation allows normal pubertal development to resume. Studies have demonstrated that children treated for CPP achieve adult heights consistent with their genetic potential, whereas untreated CPP can result in significant height loss.

Uterine Fibroids#

Triptorelin is used preoperatively for uterine fibroids to reduce fibroid size and uterine volume (typically 30-60% reduction), correct iron-deficiency anemia resulting from heavy menstrual bleeding, facilitate less invasive surgical approaches, and reduce intraoperative blood loss.

Treatment is typically limited to 3-6 months before planned surgery due to the limitations of prolonged hypoestrogenia.

Assisted Reproductive Technology#

In controlled ovarian stimulation protocols for in vitro fertilization (IVF), triptorelin is used to prevent premature LH surges that could compromise oocyte retrieval. In long-protocol IVF, triptorelin is initiated in the mid-luteal phase of the preceding cycle to achieve pituitary desensitization before gonadotropin stimulation begins.

Depot Formulations#

One of the key clinical advantages of triptorelin is the availability of extended-release depot formulations that provide sustained drug release from a single injection.

These depot formulations use biodegradable polymer microsphere technology (poly-lactic-co-glycolic acid, PLGA) that gradually releases triptorelin as the microspheres degrade. This technology eliminates the need for daily injections and improves treatment adherence, which is particularly important in oncological settings where consistent hormone suppression is critical.

Comparison with Other GnRH Agonists#

Triptorelin belongs to a class of GnRH agonist drugs that includes leuprolide (Lupron), goserelin (Zoladex), buserelin, and nafarelin. All share the same mechanism of action (pituitary desensitization) and produce similar therapeutic outcomes. The choice between agents is often based on formulation availability, dosing convenience, cost, and clinician preference rather than differences in efficacy.

Triptorelin's pharmacological profile offers certain advantages: the D-tryptophan substitution provides high receptor binding affinity and good metabolic stability, and the availability of multiple depot formulation durations provides flexibility in treatment scheduling.

Current Clinical Status#

Triptorelin is one of the most well-established peptide drugs in clinical medicine. It has decades of use across millions of patients worldwide, a robust evidence base including numerous randomized controlled trials and meta-analyses, regulatory approval in multiple countries for several indications, and well-characterized safety and side effect profiles. Research continues into additional applications including hormone receptor-positive breast cancer, transgender medicine, and fertility preservation before gonadotoxic therapy.

Key Research Findings#

An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer, published in Advances in Therapy (Merseburger AS and Hupe MC, 2016; PMID: 27246172):

Systematic review of triptorelin for prostate cancer covering efficacy, safety, depot formulations, and comparison with other GnRH agonists.

• Triptorelin effectively achieves and maintains castrate testosterone levels across all depot formulation durations
• 1-month, 3-month, and 6-month depot formulations demonstrate comparable efficacy in testosterone suppression
• Safety profile consistent with class effects of GnRH agonists; hot flashes most common adverse event

Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial, published in JAMA (Del Mastro L et al., 2011; PMID: 21771987):

Randomized study (PROMISE-GIM6) evaluating triptorelin for ovarian function preservation during chemotherapy in premenopausal breast cancer.

• Triptorelin significantly reduced the incidence of premature ovarian failure after chemotherapy
• 1-year premature ovarian failure rate: 25.9% with chemotherapy alone vs 8.9% with triptorelin plus chemotherapy
• Supports ovarian function preservation with GnRH agonist concurrent with chemotherapy

Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data, published in Journal of Clinical Oncology (Lambertini M et al., 2018; PMID: 29718793):

Meta-analysis of randomized trials evaluating GnRH agonists including triptorelin for ovarian function preservation during chemotherapy.

• GnRH agonists significantly reduced the risk of premature ovarian failure (OR 0.36, 95% CI 0.23-0.57)
• Pregnancy rate was significantly higher in the GnRH agonist group
• No negative impact on breast cancer prognosis from concurrent GnRH agonist use

Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer, published in BJU International (Heyns CF et al., 2003; PMID: 12887472):

Randomized controlled trial directly comparing triptorelin with leuprolide for advanced prostate cancer.

• Triptorelin and leuprolide produced equivalent testosterone suppression to castrate levels
• No significant differences in efficacy outcomes between the two agents
• Safety profiles were comparable between triptorelin and leuprolide

Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis, published in European Urology (Bosco C et al., 2015; PMID: 25484142):

Population-based study evaluating cardiovascular risk associated with GnRH agonist therapy in prostate cancer patients.

• GnRH agonist use was associated with increased risk of cardiovascular events compared to non-ADT controls
• Risk was highest in the first year of therapy
• Cardiovascular monitoring recommended for patients initiating GnRH agonist therapy

Related Reading#

• Triptorelin research studies and evidence
• Triptorelin dosing protocols
• Triptorelin side effects profile
• Gonadorelin research guide
• HCG research guide